Polycystic Ovary Syndrome Treatment Using DLBS3233, Metformin, and Combination of Both, and Its Relation to Fertility
Phase of Trial: Phase III
Latest Information Update: 09 May 2017
At a glance
- Drugs DLBS 3233 (Primary) ; Metformin
- Indications Insulin resistance; Polycystic ovary syndrome
- Focus Therapeutic Use
- Acronyms POSITIF
- Sponsors Dexa Medica
- 10 Jun 2017 Biomarkers information updated
- 02 May 2017 Planned End Date changed from 1 Dec 2017 to 1 Oct 2018.
- 02 May 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Aug 2018.